NSE: MARKSANS | BSE: 524404

Strong Performer, Getting Expensive

Download real time

330.40 0.25 (0.08%)

New 52W High in past week

1.4M NSE+BSE Volume

NSE 10 Sep, 2026 3:31 PM (IST)

14,972.5

Market Cap

High in industry

Beta 1Year

Average volatility

Marksans Pharma Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for MARKSANS, BSE:524404 Marksans Pharma Ltd.

Search Inside the pdf :

Marksans Pharma Ltd.

31 Aug 2026

330.40

0.08%

Axis Punch:Marksans Pharma

Buy: Marksans Pharma Ltd.

Axis Direct

We recommend a BUY on the stock with a target price of Rs 362/share, implying an upside of 10% from the CMP.

Marksans Pharma has gained 30.72% in the last 3 Months

Marksans Pharma Ltd.

14 Mar 2024

330.40

0.08%

MARKSANS PHARMA LTD.

Buy: Marksans Pharma Ltd.

Target

Ventura

Growth in demand and capabilities

Marksans Pharma has gained 30.72% in the last 3 Months

Marksans Pharma Ltd.

04 Oct 2023

330.40

0.08%

MARKSANS PHARMA LTD.

Buy: Marksans Pharma Ltd.

Target

Ventura

Consolidating on the back of the Teva acquisition

Marksans Pharma Ltd. is trading above all available SMAs

Marksans Pharma Ltd.

22 Jul 2023

330.40

0.08%

Strong growth in OTC business to drive profitability

Buy: Marksans Pharma Ltd.

StoxBox - BP Wealth

Marksans Pharma has entered into a Business Transfer Agreement with Tevapharm to acquire its business relating to the manufacture and supply of bulk pharmaceutical formulations in Goa. The company plans to manufacture tablets, hard and soft gel capsules, ointments, gummies, and creams from the new capacity.

Axis Direct released a Buy report for Marksans Pharma Ltd. with a price target of 362.0 on 31 Aug, 2026.

Marksans Pharma Ltd.

21 Oct 2022

330.40

0.08%

MARKSANS PHARMA LTD.

Buy: Marksans Pharma Ltd.

Ventura

Growth visibility with reasonable valuation

Marksans Pharma has gained 20.65% in the last 1 Month

Marksans Pharma Ltd.

06 Jun 2022

330.40

0.08%

Marksans Pharma

Buy: Marksans Pharma Ltd.

Target

Arihant Capital

Marksans Pharma Ltd. has an average target of 362.00 from 1 broker.

Marksans Pharma Ltd.

14 Oct 2021

330.40

0.08%

Marksans Pharma

Buy: Marksans Pharma Ltd.

Arihant Capital

We had hosted Investor Conference on 29th & 30th September 2021 where 15 companies participated at our Arihant Rising Star's Virtual Summit. Key takeaways from the conference are as follows:...

Marksans Pharma has gained 20.65% in the last 1 Month

Marksans Pharma Ltd.

11 Jun 2018

330.40

0.08%

Marksans Pharma

Hold: Marksans Pharma Ltd.

Recommendation Target

Centrum Broking

Source: Bloomberg, Centrum Research, *as on 8th June 2018 Recommendation and key risks: We have revised our FY19E and FY20E EPS downwards by 41% and 43% respectively. We downgrade MPL to Hold from Buy rating, with a TP of Rs31 based on 18x March'20E EPS of Rs1.7, and a 10.2%% upside from CMP. Key positive upsides would be additional ANDA approvals from US FDA...